Reviewing Entrada Therapeutics (NASDAQ:TRDA) and Immuneering (NASDAQ:IMRX)
by Kim Johansen · The Markets DailyEntrada Therapeutics (NASDAQ:TRDA – Get Free Report) and Immuneering (NASDAQ:IMRX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.
Insider and Institutional Ownership
86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 22.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Entrada Therapeutics and Immuneering”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Entrada Therapeutics | $5.74 million | 47.97 | -$143.75 million | ($3.99) | -1.78 |
| Immuneering | N/A | N/A | -$56.03 million | ($1.17) | -3.77 |
Immuneering has lower revenue, but higher earnings than Entrada Therapeutics. Immuneering is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Entrada Therapeutics and Immuneering’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entrada Therapeutics | -2,895.05% | -51.22% | -42.20% |
| Immuneering | N/A | -31.93% | -29.92% |
Analyst Recommendations
This is a summary of recent ratings and target prices for Entrada Therapeutics and Immuneering, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entrada Therapeutics | 1 | 2 | 3 | 0 | 2.33 |
| Immuneering | 1 | 0 | 4 | 1 | 2.83 |
Entrada Therapeutics presently has a consensus price target of $17.50, indicating a potential upside of 146.83%. Immuneering has a consensus price target of $16.50, indicating a potential upside of 274.15%. Given Immuneering’s stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than Entrada Therapeutics.
Risk and Volatility
Entrada Therapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500.
Summary
Immuneering beats Entrada Therapeutics on 11 of the 14 factors compared between the two stocks.
About Entrada Therapeutics
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
About Immuneering
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.